Patients with moderate COVID-19 appeared to benefit from early administration of aspirin, according to a new study. Patients who were given aspirin on their first day in the hospital were less likely to die or experience blood clotting, researchers found. Dr. Jonathan Chow with the George Washington University School of Medicine and Health Sciences and other researchers analyzed data from 64 healthcare systems for the study. Moderate COVID-19 was defined as not needing intensive care such as mechanical ventilation of oxygenation. Out of 112,269 patients with moderate COVID-19, approximately 15,200 received aspirin on the first day of admission. The median duration of aspirin administration was five days. Researchers found the in-hospital mortality rate at 28 days post-admission was lower in the aspirin group, 10.2 percent compared to 11.8 percent. They estimated giving 63 patients aspirin early on would prevent one in-hospital death. Separating patients by age groups and underlying health …